Premium
Anticholinergic anti‐Parkinson drug prescription in haloperidol‐treated patients: A population‐based study
Author(s) -
Diana Giovanni,
Alegiani Stefania Spila,
Fortini Marco,
Raschetti Roberto
Publication year - 1993
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.2630020109
Subject(s) - anticholinergic , medicine , haloperidol , medical prescription , logistic regression , pharmacoepidemiology , extrapyramidal symptoms , anesthesia , population , psychiatry , antipsychotic , pharmacology , schizophrenia (object oriented programming) , environmental health , dopamine
Anticholinergic anti‐Parkinson drugs are often used to prevent or treat neuroleptic‐induced extrapyramidal side effects. National Health Service prescriptions for these drugs and haloperidol delivered in the geographical area of Rome, Italy, and the surrounding province (about 3,750,000 inhabitants) from 1986 to 1989 were reviewed. Individual prescription histories were reconstructed and analysed with a computerized procedure. Over the four years 1121 (32.2%) of the 3478 haloperidol‐treated individuals studied were concurrently prescribed anticholinergic anti‐Parkinson drugs. Their distribution shows an age‐related decrease, the percentage ranging from 50.7 (age 16–27) to 17.7 (ages over 80). The analysis of results by logistic regression also demonstrates that the probability of receiving anticholinergic anti‐Parkinson medication is higher in women and correlates with the amount of haloperidol prescribed.